Leukemia & Lymphoma

Top-read articles

76 reads in the past 30 days

Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study

March 2025

115 Reads

[...]

37 reads in the past 30 days

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis

March 2025

85 Reads

[...]

14 reads in the past 30 days

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis

January 2025

102 Reads

2 Citations

[...]

12 reads in the past 30 days

A current view of the pathogenesis and treatment of primary cutaneous diffuse large B cell lymphoma - leg type

May 2025

12 Reads

Ewa Robak

Marcin Braun

Tadeusz Robak

11 reads in the past 30 days

Novel isolated mutations at the C515 residue of BTK in a CLL patient associated with acalabrutinib resistance

May 2025

15 Reads

2 Citations

Maria Dimou

Maria Karypidou

Aikaterini Bitsani

[...]

Panayiotis panayiotidis

Publishes research on hematological cancers, covering disease biology, novel agents, chemotherapy, pharmacology/pharmacogenomics, ethics and epidemiology.

Leukemia & Lymphoma is an international peer reviewed journal that publishes research on all aspects of hematological malignancies.

The journal aims to address the needs of physicians and scientists interested in clinical, translational, laboratory and basic science research, as well as clinical diagnosis and treatment of patients with malignant hematological disorders.

Leukemia & Lymphoma covers from clinical and clinico-pathological investigations to fundamental research in the following topics: disease biology; mechanisms of action of novel agents; development of combination chemotherapy; pharmacology and pharmacogenomics; ethics and epidemiology.

Submissions of unique clinical observations or confirmatory studies are considered and…

For a full list of the subject areas this journal covers, please visit the journal website.

Optimal timing of allogeneic hematopoietic stem cell transplant in MDS

Literature Review

June 2025

5 Reads

Kristin Rathje

Nicolaus Kröger

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma

Article

June 2025

6 Reads

[...]

Lower-dose venetoclax (LoVe) based regimes in children with acute leukemia

Article

June 2025

15 Reads

[...]

Tablet venetoclax 100 mg along with tablet posaconazole 300 mg once a day for 7 days was used in 4 of the older children. The 2-year-old child received venetoclax 50 mg and posaconazole 100 mg once a day for 7 days. Posaconazole was added to use the drug interaction with venetoclax to the patient’s financial advantage where 100 mg is equivalent to 400 mg and to provide additional antifungal prophylaxis. Two children developed grade I transaminitis. None developed hyperbilirubinemia. All three children with ALL [2 Early T-cell precursor (ETP) ALL and 1 B-ALL) attained MRD-negative remission. None of the 2 children with acute myeloid leukemia (AML) showed any response. Both were shifted to best supportive care and quickly succumbed thereafter.

Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada